NO20072285L - S-mirtazapin for behandling av hetetokter - Google Patents

S-mirtazapin for behandling av hetetokter

Info

Publication number
NO20072285L
NO20072285L NO20072285A NO20072285A NO20072285L NO 20072285 L NO20072285 L NO 20072285L NO 20072285 A NO20072285 A NO 20072285A NO 20072285 A NO20072285 A NO 20072285A NO 20072285 L NO20072285 L NO 20072285L
Authority
NO
Norway
Prior art keywords
mirtazapine
treatment
hot flashes
flashes
hot
Prior art date
Application number
NO20072285A
Other languages
English (en)
Norwegian (no)
Inventor
Bernardus Wijnand Math Peeters
Anton Egbert Peter Adang
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072285(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv filed Critical Organon Nv
Publication of NO20072285L publication Critical patent/NO20072285L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20072285A 2004-11-15 2007-04-30 S-mirtazapin for behandling av hetetokter NO20072285L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105778 2004-11-15
PCT/EP2005/055947 WO2006051111A1 (fr) 2004-11-15 2005-11-14 S-mirtazapine pour le traitement des bouffées de chaleur

Publications (1)

Publication Number Publication Date
NO20072285L true NO20072285L (no) 2007-06-13

Family

ID=34929859

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072285A NO20072285L (no) 2004-11-15 2007-04-30 S-mirtazapin for behandling av hetetokter

Country Status (31)

Country Link
US (4) US20070265245A1 (fr)
EP (1) EP1814555B1 (fr)
JP (1) JP2008519810A (fr)
KR (1) KR20070085470A (fr)
CN (2) CN101056641A (fr)
AR (1) AR053780A1 (fr)
AT (1) ATE439843T1 (fr)
AU (1) AU2005303778B2 (fr)
BR (1) BRPI0517818A2 (fr)
CA (1) CA2587283C (fr)
CY (1) CY1110538T1 (fr)
DE (1) DE602005016141D1 (fr)
DK (1) DK1814555T3 (fr)
ES (1) ES2329815T3 (fr)
HK (1) HK1104235A1 (fr)
HR (1) HRP20090513T1 (fr)
IL (1) IL182767A (fr)
MX (1) MX2007005827A (fr)
MY (1) MY144089A (fr)
NO (1) NO20072285L (fr)
NZ (1) NZ554858A (fr)
PE (1) PE20061051A1 (fr)
PL (1) PL1814555T3 (fr)
PT (1) PT1814555E (fr)
RS (1) RS51138B (fr)
RU (1) RU2396957C2 (fr)
SI (1) SI1814555T1 (fr)
TW (1) TW200631584A (fr)
UA (1) UA88655C2 (fr)
WO (1) WO2006051111A1 (fr)
ZA (1) ZA200703884B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002174A2 (fr) * 2005-06-27 2007-01-04 N.V. Organon. Procede de traitement de symptomes vasomoteurs induits par la depletion hormonale
US20070129611A1 (en) * 2005-12-06 2007-06-07 University Of North Texas Health Science Center At Fort Worth System, Method and Apparatus for Assessing Menopausal or Post-Hysterectomy Symptoms
MX2008011434A (es) * 2006-03-06 2008-11-18 Organon Nv Metodo mejorado para retirar del tratamiento hormonal los sintomas vasomotores inducidos por eliminación de hormonas.
WO2008062021A1 (fr) * 2006-11-22 2008-05-29 N.V. Organon Systeme de liberation vaginale de mirtazapine
US7645750B2 (en) 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
JP2009018992A (ja) 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
DK3261645T3 (da) 2015-02-27 2021-06-07 Dechra Ltd Stimulering af appetit, håndtering af vægttab og behandling af anoreksi hos hunde og katte
AU2018274767A1 (en) * 2017-05-25 2020-01-30 Glytech Llc. Combined therapy for NMDAR antagonist-responsive neuropsychiatric disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPH1187727A (ja) * 1997-09-12 1999-03-30 Mitsubishi Electric Corp 半導体装置
BR9909357A (pt) * 1998-04-02 2000-12-12 Akzo Nobel Nv Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina

Also Published As

Publication number Publication date
ES2329815T3 (es) 2009-12-01
BRPI0517818A2 (pt) 2010-03-16
MY144089A (en) 2011-08-15
SI1814555T1 (sl) 2009-12-31
RU2396957C2 (ru) 2010-08-20
HK1104235A1 (en) 2008-01-11
AR053780A1 (es) 2007-05-23
JP2008519810A (ja) 2008-06-12
CN101056641A (zh) 2007-10-17
US20100267694A1 (en) 2010-10-21
TW200631584A (en) 2006-09-16
US20130225559A1 (en) 2013-08-29
RU2007122391A (ru) 2008-12-20
CN102772414A (zh) 2012-11-14
CY1110538T1 (el) 2015-04-29
IL182767A (en) 2011-07-31
EP1814555B1 (fr) 2009-08-19
UA88655C2 (ru) 2009-11-10
IL182767A0 (en) 2007-09-20
PE20061051A1 (es) 2006-10-26
HRP20090513T1 (en) 2009-10-31
DK1814555T3 (da) 2009-12-07
US20070265245A1 (en) 2007-11-15
CA2587283C (fr) 2013-01-15
EP1814555A1 (fr) 2007-08-08
PL1814555T3 (pl) 2010-01-29
US20120302552A1 (en) 2012-11-29
DE602005016141D1 (de) 2009-10-01
CA2587283A1 (fr) 2006-05-18
PT1814555E (pt) 2009-09-30
RS51138B (sr) 2010-10-31
ATE439843T1 (de) 2009-09-15
NZ554858A (en) 2009-10-30
AU2005303778A1 (en) 2006-05-18
WO2006051111A1 (fr) 2006-05-18
KR20070085470A (ko) 2007-08-27
ZA200703884B (en) 2009-07-29
AU2005303778B2 (en) 2011-02-17
MX2007005827A (es) 2007-07-20

Similar Documents

Publication Publication Date Title
NO20072285L (no) S-mirtazapin for behandling av hetetokter
NO20076206L (no) Kombinasjon av PDE4 inhibitor romflumilast og et tetrahydrobioterin-derivativ
AP2327A (en) Quinoline derivatives for the treatment of latent tuberculosis.
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
DE602005014127D1 (de) Medizinische vorrichtung und herstellungsverfahren dafür
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
NO20070782L (no) Tetrapeptidanaloger.
IS7699A (is) Afleiður af díoxan-2-alkýl karbamötum, framleiðslu aðferð þeirra og notkun við meðferð sjúkdóma
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
ATE474617T1 (de) Medizinproduktsysteme
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
DK2073811T3 (da) Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1765322T3 (da) Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser
DK1848415T3 (da) Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
EP1827478A4 (fr) Methodes de traitement d'articulations lesees ou malades
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
DK2422786T3 (da) Nye lægemiddelkombinationer til behandling af luftvejssygdomme
NO20054494L (no) Peptidvektorer
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application